The FDA has approved Journavx, a groundbreaking non-opioid painkiller, marking the first new class in over 20 years, aiming to eliminate the risks of opioid addiction.
President Trump has rescinded Biden's order aimed at lowering prescription drug costs, raising concerns about potential future increases in prices for Medicare beneficiaries.